Systemic inflammation and sepsis. Part I: Storm formation

Juan B Dartiguelongue, Juan B Dartiguelongue

Abstract

Sepsis is still a major cause of morbidity and mortality. It results from a dysregulated immune response to infection that leads to organ and system dysfunction. The inflammatory response to pathogenic microorganisms implies a dynamic, complex chain of events leading to endothelial and immune system activation. The purpose of this process is to control infection and repair tissues. However, both host and microorganism factors may result in severe forms of systemic inflammation with a high mortality rate. Sepsis falls within this complex scenario, where the inflammatory storm and the causative microorganism converge in a severe multisystem presentation. This manuscript is divided into two parts. Part I describes the mechanisms triggering systemic inflammation and progression to sepsis, together with its main biological markers. Part II analyzes the mechanisms leading to organ dysfunction.

Keywords: cytokines; sepsis; septic shock; systemic inflammatory response syndrome.

Conflict of interest statement

None

Sociedad Argentina de Pediatría.

References

    1. Singer M, Deutschman C, Seymour CW, Shankar-Hari M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10.
    1. Watson RS, Carcillo JA, Linde-Zwible WT, Clermont G, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003; 167(5):695-701.
    1. De Souza DC, Machado FR. Epidemiology of Pediatric Septic Shock. J Pediatr Intensive Care. 2019; 8(1):3-10.
    1. Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a primer. Crit Care Med. 2009; 37(1):291-304.
    1. Bateman S, Seed P. Procession to Pediatric Bacteremia and Sepsis: Covert Operations and Failures in Diplomacy. Pediatrics. 2010; 126(1):137-50.
    1. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med. 1996; 125(8):680-7.
    1. Clapp DW. Developmental regulation of the immune system. Semin Perinatol. 2006; 30(2):69-72.
    1. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008; 8(10):776-87.
    1. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005; 6(1):2-8.
    1. Van Amersfoort ES, Van Berkel TJ, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev. 2003; 16(3):379-414.
    1. Dixon DR, Darveau RP. Lipopolysaccharide heterogeneity: innate host response to bacterial modifications of lipid structure. J Dent Res. 2005; 84(7):584-95.
    1. Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010; 10(12):826-37.
    1. Elson G, Dunn-Siegrist I, Daubeuf B, Pugin J. Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria. Blood. 2007; 109(4):1574-83.
    1. Van der Poll T, Lowry SF. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense? Shock. 1995; 3(1):1-12.
    1. Pinsky MR, Vincent JL, Deviere J, Alegre M, et al. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest. 1993; 103(2): 565- 75.
    1. Pruitt JH, Copeland EM 3rd, Moldawer LL. Interleukin-1 and Interleukin-1 antagonism in sepsis, systemic inflammatory response syndrome, and septic shock. Shock. 1995; 3(4):235-51.
    1. Fresno M, Kopf M, Rivas L. Cytokines and infectious diseases. Immunol Today. 1997; 18(2):56-8.
    1. Walport MJ. Complement. First of two parts. N Engl J Med. 2001; 344(14):1058-66.
    1. Walport MJ. Complement. Second of two parts. N Engl J Med. 2001; 344(15):1140-4.
    1. Monk PN, Scola AM, Madala P, Fairlie DP. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol. 2007; 152(4):429-48.
    1. Riedemann NC, Guo RF, Neff TA, Laudes IJ, et al. Increased C5a receptor expression in sepsis. J Clin Invest. 2002; 110(1):101-8.
    1. Kawasaki T. Update on pediatric sepsis: a review. J Intensive Care. 2017; 5:47.
    1. Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med. 1998; 24(8):888-9.
    1. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med. 1999; 27(7):1230-51.
    1. Furebring M, Hakansson LD, Venge P, Nilsson B, et al. Expression of the C5a receptor (CD88) on granulocytes and monocytes in patients with severe sepsis. Crit Care. 2002; 6(4):363-70.
    1. Huber-Lang MS, Younkin EM, Sarma JV, McGuire SR, et al. Complement-induced impairment of innate immunity during sepsis. J Immunol. 2002; 169(6):3223-31.
    1. Liu D, Lu F, Qin G, Fernandes SM, et al. C1 inhibitor-mediated protection from sepsis. J Immunol. 2007; 179(6):3966-72.
    1. Liu D, Cai S, Gu X, Scafidi J, et al. C1 inhibitor prevents endotoxin shock via direct interaction with lipopolysaccharide. J Immunol. 2003; 171(5):2594-601.
    1. Giamarellos-Bourboulis EJ, Opal SM. The role of genetics and antibodies in sepsis. Ann Transl Med. 2016; 4(17):328.
    1. Lamping N, Dettmer R, Schröder NW, Pfiel D, et al. LPS- binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest. 1998; 101(10):2065-71.
    1. Suffredini AF, Fromm RE, Parker MM, Brenner M, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989; 321(5): 280-7.
    1. Tapper H, Herwald H. Modulation of hemostatic mechanisms in bacterial infectious diseases. Blood. 2000; 96(7):2329-37.
    1. Marshall JC, Foster D, Vincent JL, Cook D, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis. 2004; 190(3):527-34.
    1. Minasyan H. Sepsis: mechanisms of bacterial injury to the patient. Scand J Trauma Resusc Emerg Med. 2019; 27(1):19.
    1. Minasyan H. Sepsis and septic shock: Pathogenesis and treatment perspectives. J Crit Care. 2017; 40:229-42.
    1. Vincent JL. The clinical challenge of sepsis identification and monitoring. PLoS Med. 2016; 13(5):e1002022.
    1. Sager R, Kutz A, Mueller B, Schuetz P. Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Med. 2017; 15(1):15.
    1. Gregoriano C, Heilmann E, Molitor A, Schuetz P. Role of procalcitonin use in the management of sepsis. J Thorac Dis. 2020; 12(Suppl 1):S5-15.
    1. Beltra JC, Decaluwe H. Cytokines and persistent viral infections. Cytokine. 2016; 82:4-15.
    1. Degré M. Interferons and other cytokines in bacterial infections. J Interferon Cytokine Res. 1996; 16(6):417-26.
    1. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem. 2004; 279(47):48487-90.
    1. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005; 117(2):104-11.
    1. Alagarasu K, Selvaraj P, Swaminathan S, Raghavan S, et al. Mannose binding lectin gene variants and susceptibility to tuberculosis in HIV-1 infected patients of South India. Tuberculosis (Edinb). 2007; 87(6):535-43.
    1. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013; 13(5): 426-35.
    1. Ramsay ES, Lerman MA. How to use the erythrocyte sedimentation rate in paediatrics. Arch Dis Child Educ Pract Ed. 2015; 100(1):30-6.
    1. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011; 9:107.
    1. Wirz Y, Meier M, Bouadma L, Luyt C, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized Trials. Crit Care. 2018; 22(1):191.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever